F

Fate Therapeutics
D

FATE

1.41000
USD
-0.14
(-8.74%)
مغلق
حجم التداول
69,701
الربح لكل سهم
-2
العائد الربحي
-
P/E
-1
حجم السوق
160,591,010
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    B
    BLUE
    -2.93000
    (-41.68%)
    4.10000 USD
    C
    CLLS
    -0.02000
    (-1.30%)
    1.52000 USD
    C
    CRSP
    -2.620
    (-5.19%)
    47.840 USD
    E
    EDIT
    -0.14000
    (-6.80%)
    1.92000 USD
    N
    NTLA
    -0.075
    (-0.61%)
    12.180 USD
    S
    SGMO
    -0.04500
    (-4.00%)
    1.08000 USD
    V
    VYGR
    -0.04000
    (-0.94%)
    4.22500 USD
    المزيد
الأخبار
المقالات

العنوان: Fate Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.